Combinati developed a digital PCR platform for accurate, precise absolute quantification of disease-relevant biomarkers over time
Combinati developed a digital PCR platform for accurate, precise absolute quantification of disease-relevant biomarkers over time. Its system combines a single instrument and consumable with microfluidic sample partitioning, low-waste operation, false-positive rejection, and compatibility with traditional qPCR assays. Thermo Fisher Scientific acquired the company and its digital PCR technology in 2021.